The American Kratom Association (AKA) has formally requested FDA Commissioner Robert Califf to convene a public stakeholder meeting on kratom regulatory policies. In a letter dated September 4, 2024, the AKA highlighted inconsistencies in the FDA’s stance on kratom, noting that the agency has yet to definitively determine if kratom poses a danger to public health.
The AKA argues that the FDA has relied on questionable evidence to justify restricting access to kratom products. They hope this meeting will allow for a comprehensive evaluation of current science, consumer experiences, and expert opinions to shape a more informed regulatory approach.
Mac Haddow, Senior Fellow on Public Policy for the AKA, emphasized the importance of this two-way engagement in developing the best regulatory policy for kratom. The full details of the AKA’s request can be found on WRAL’s website.
